Defunct Company
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
129
NCT01945021
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
Phase: Phase 2
Role: Collaborator
Start: Sep 30, 2013
Completion: Jan 22, 2020